AR101 Oral Immunotherapy for Peanut Allergy.

Brian P Vickery,Andrea Vereda, Thomas B Casale,Kirsten Beyer,George du Toit,Jonathan O Hourihane,Stacie M Jones,Wayne G Shreffler, Annette Marcantonio,Rezi Zawadzki,Lawrence Sher,Warner W Carr,Stanley Fineman, Leon Greos,Rima Rachid,M Dolores Ibáñez,Stephen Tilles,Amal H Assa’ad,Caroline Nilsson,Ned Rupp,Michael J Welch,Gordon Sussman,Sharon Chinthrajah,Katharina Blumchen,Ellen Sher,Jonathan M Spergel,Frederick E Leickly,Stefan Zielen, Julie Wang,Georgiana M Sanders,Robert A Wood,Amarjit Cheema,Carsten Bindslev-Jensen,Stephanie Leonard, Rita Kachru,Douglas T Johnston, Frank C Hampel,Edwin H Kim,Aikaterini Anagnostou,Jacqueline A Pongracic,Moshe Ben-Shoshan, Hemant P Sharma,Allan Stillerman,Hugh H Windom,William H Yang,Antonella Muraro,José M Zubeldia,Vibha Sharma,Morna J Dorsey,Hey J Chong, Jason Ohayon,J Andrew Bird, Tara F Carr,Dareen Siri,Montserrat Fernández-Rivas,David K Jeong,David M Fleischer, Jay A Lieberman,Anthony E J Dubois, Marina Tsoumani,Christina E Ciaccio,Jay M Portnoy,Lyndon E Mansfield, Stephen B Fritz,Bruce J Lanser,Jonathan Matz,Hanneke N G Oude Elberink,Pooja Varshney, Stephen G Dilly,Daniel C Adelman,A Wesley Burks

The New England journal of medicine（2018）

Cited 0|Views5

No score

Abstract

In this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut, treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo. (Funded by Aimmune Therapeutics; PALISADE ClinicalTrials.gov number, NCT02635776 .).

Translated text

Key words

peanut

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined